NASDAQ:REUN Reunion Neuroscience (REUN) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.12▼$1.1250-Day Range$1.11▼$1.1352-Week Range$0.63▼$5.07VolumeN/AAverage Volume210,209 shsMarket Capitalization$13.13 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 ProfileProfileAnalyst RatingsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Reunion Neuroscience (NASDAQ:REUN) StockReunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.Read More REUN Stock News HeadlinesSeptember 23, 2023 | dallasnews.comHeart disease survivors reflect at American Heart Association’s annual walk in DallasAugust 14, 2023 | markets.businessinsider.comPsyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & MoreOctober 1, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 3, 2023 | theglobeandmail.comClosing Bell: Reunion Neuroscience Inc flat on Friday (REUN)August 3, 2023 | benzinga.comReunion Neuroscience Completes Take-Private Setup: Delisting & Consideration DetailsJuly 17, 2023 | msn.comReunion Neuroscience On The Brink Of Going Private With Final Court ApprovalJuly 14, 2023 | financialpost.comReunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of ArrangementJune 29, 2023 | msn.comReunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3October 1, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.June 29, 2023 | finanznachrichten.deReunion Neuroscience Inc.: Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateJune 29, 2023 | msn.comReunion Neuroscience: Q4 Earnings InsightsJune 29, 2023 | msn.comRecap: Reunion Neuroscience Q4 EarningsJune 29, 2023 | finance.yahoo.comReunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateJune 17, 2023 | theglobeandmail.comClosing Bell: Reunion Neuroscience Inc down on Friday (REUN)June 1, 2023 | marketwatch.comReunion Neuroscience to Be Acquired in $13.1 Million DealJune 1, 2023 | msn.comReunion Neuroscience jumps 91% on acquisition by MPM BioImpactJune 1, 2023 | finance.yahoo.comReunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpactMay 20, 2023 | theglobeandmail.comClosing Bell: Reunion Neuroscience Inc up on Friday (REUN)May 18, 2023 | theglobeandmail.comClosing Bell: Reunion Neuroscience Inc down on Thursday (REUN)May 4, 2023 | theglobeandmail.comClosing Bell: Reunion Neuroscience Inc up on Wednesday (REUN)May 2, 2023 | theglobeandmail.comClosing Bell: Reunion Neuroscience Inc up on Monday (REUN)May 2, 2023 | theglobeandmail.comReunion Neuroscience: Top 10 Undervalued Healthcare Sector Stocks on TSX (REUN)April 26, 2023 | marketwatch.comReunion Neuroscience Gets Nasdaq Notice of Minimum Bid-Price DeficiencyApril 25, 2023 | finance.yahoo.comReunion Neuroscience Receives NASDAQ Notification Regarding Minimum Bid Price DeficiencyApril 25, 2023 | finance.yahoo.comReunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 13, 2023 | theglobeandmail.comClosing Bell: Reunion Neuroscience Inc down on Wednesday (REUN)April 3, 2023 | finance.yahoo.comReunion Neuroscience Appoints Dr. Fred Grossman to Board of DirectorsSee More Headlines Receive REUN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address REUN Company Calendar Today10/01/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Health services Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REUN CUSIPN/A CIK1865482 Webwww.reunionneuro.com Phone1-833-222-0084Fax1-855-933-1211Employees16Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.50 High Stock Price Forecast$20.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+1,283.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,690,000.00 Net MarginsN/A Pretax Margin-2,583.10% Return on Equity-91.82% Return on Assets-64.58% Debt Debt-to-Equity RatioN/A Current Ratio3.51 Quick Ratio3.51 Sales & Book Value Annual Sales$3.88 million Price / Sales3.38 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book0.82Miscellaneous Outstanding Shares11,720,000Free FloatN/AMarket Cap$13.13 million OptionableNot Optionable Beta2.29 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Hannan Fleiman (Age 42)Co-Founder & Non-Independent Director Comp: $214.69kDr. Nathan Bryson B.Sc. (Age 59)Ph.D., Chief Science Officer Comp: $312.47kMr. Gregory T. Mayes Esq. (Age 54)J.D., Pres, CEO & Director Mr. Edward F. Smith CPA (Age 52)Chief Financial Officer Mr. Curtis WeberGen. CounselMr. Stephan CoteHead of QualityDr. Robert Alexander M.D.Chief Medical Officer & Sr. AdvisorMore ExecutivesKey CompetitorsBetter TherapeuticsNASDAQ:BTTXUpHealthNYSE:UPHPear TherapeuticsNASDAQ:PEAREUDA HealthNASDAQ:EUDANeuroBo PharmaceuticalsNASDAQ:NRBOView All CompetitorsInstitutional OwnershipBeryl Capital Management LLCBought 687,631 shares on 8/15/2023Ownership: 5.867%AdvisorShares Investments LLCSold 71,200 shares on 8/9/2023Ownership: 2.315%View All Institutional Transactions REUN Stock - Frequently Asked Questions Should I buy or sell Reunion Neuroscience stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reunion Neuroscience in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REUN shares. View REUN analyst ratings or view top-rated stocks. What is Reunion Neuroscience's stock price forecast for 2023? 5 Wall Street research analysts have issued 12-month price targets for Reunion Neuroscience's shares. Their REUN share price forecasts range from $11.00 to $20.00. On average, they predict the company's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 1,283.9% from the stock's current price. View analysts price targets for REUN or view top-rated stocks among Wall Street analysts. What is Reunion Neuroscience's stock symbol? Reunion Neuroscience trades on the NASDAQ under the ticker symbol "REUN." What is Reunion Neuroscience's stock price today? One share of REUN stock can currently be purchased for approximately $1.12. How much money does Reunion Neuroscience make? Reunion Neuroscience (NASDAQ:REUN) has a market capitalization of $13.13 million and generates $3.88 million in revenue each year. How can I contact Reunion Neuroscience? Reunion Neuroscience's mailing address is 30 DUNCAN STREET SUITE 400, TORONTO A6, M5V 2C3. The official website for the company is www.reunionneuro.com. The company can be reached via phone at 1-833-222-0084, via email at investors@fieldtriphealth.com, or via fax at 1-855-933-1211. This page (NASDAQ:REUN) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reunion Neuroscience Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.